Navigation Links
Medivir Reshapes Drug Discovery

Chooses Waters Synapt High Definition MS (HDMS) System to Aid


MILFORD, Mass., Nov. 8 /PRNewswire-FirstCall/ -- Swedish-based biotechnology firm Medivir AB has chosen the Waters(R) Synapt(TM) HDMS System to hasten its drug discovery efforts in the area of protease inhibitor research and eventually help patients who suffer with herpes, hepatitis C, HIV, osteoporosis, osteoarthritis, and high blood pressure. Installed in June, the Synapt High Definition Mass Spectrometry(TM) (MS) System is yielding significant information that is assisting with the decision-making process and helping Medivir reach its drug discovery milestones.

"Medivir is constantly reviewing opportunities to improve research output both in terms of quantity and quality. This investment in the Waters Synapt HDMS instrument has been seen as a very important vehicle to increase research output and to provide high quality support for the discovery disciplines," said Medivir Vice President of Discovery Research, Bertil Samuellson, Ph.D.

In terms of helping Medivir advance its research, the Synapt HDMS(TM) System carries great potential.

"The sensitivity of this instrument is significantly greater than the average quadrupole time-of-flight instrument and gives us more complete metabolic profiles," says Kurt Benkestock, Senior Research Scientist, Analytical Chemistry Department, who supports many of Medivir's research efforts. "At one time, we relied on outside resources to give us the information we needed. Now with the Synapt HDMS System, we can acquire the data we need in house and move candidates into advanced development phases faster."

After carefully evaluating all its options, Medivir chose Waters Synapt HDMS System coupled to a Waters ACQUITY(R) UltraPerformance LC(R) (UPLC(R)) System over all the conventional high-resolution, two-dimensional LC-MS technologies offered by other mass spectrometry suppliers. "The reason we went with Waters Synapt System is that the instrument outperformed the others based on 22 performance criteria," says Benkestock.

Other intangible aspects of the selection process were important as well. "Waters is good at listening to its customers, understanding their requirements, and adding features and making improvements that help us meet our scientific requirements," added Benkestock.

Benkestock's plans for the Synapt HDMS System are far-ranging including structure elucidation of metabolites and impurities, ligand screening during early drug discovery, protein and peptide work, protein identification and studying post-translation modifications, and target characterization.

Medivir gave its employees a better look at the Synapt HDMS System during an inauguration event on Thursday, October 25 at corporate headquarters.

Waters introduced the Synapt HDMS System at the American Society of Mass Spectrometry annual meeting in Seattle in June of 2006. It is the first commercially-available mass spectrometer with the ability to analyze ions by their size, shape and charge in addition to mass.

Other customers include Cambridge University, Oxford University, Utrecht University, University of Leeds, Max Planck Institute, and the University of Warwick.

For more information:

About Medivir AB (

Medivir aims to develop protease inhibitors into innovative pharmaceuticals to be used against major widespread diseases and improve the quality of life for a number of patient groups. Medivir has several partnerships with pharmaceutical companies and has one investigational drug in phase III clinical trials, three in phase II and two in phase I. Other protease projects are in the late preclinical stage.

About Waters Corporation (

Waters Corporation (NYSE: WAT) creates business advantage for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.28 billion in 2006 and 4,700 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters, ACQUITY, UltraPerformance LC, UPLC, Synapt, High Definition MS, High Definition Mass Spectrometry, and HDMS are trademarks of Waters Corporation.

Media Contact:

Brian J. Murphy

Waters Corporation


SOURCE Waters Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Discovery of sugar sensor in intestine could benefit diabetes
2. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
3. Stem cell research produces a key discovery for Fragile X Syndrome
4. Welch Foundation gives $1.6 million for drug discovery research
5. New discovery leaves blood-doping athletes scratching their heads
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. New discovery leaves blood-doping athletes scratching their heads
8. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
9. Discovery supports theory of Alzheimers disease as form of diabetes
10. Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits
11. New discovery may improve treatment of one of the worlds leading causes of blindness
Post Your Comments:
(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... health and wellness consultation, has collaborated with Women’s Web – an online ... queries on topics on mental and emotional well-being relationship, life balance, stress, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... for all, Water For Empowerment ™ attracts volunteers together who want to ... by empowering women as key stakeholders in the process. The non-profit launched its ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Italian therapeutic drug monitoring ...
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare industry ... over 2015-2016. Latin America has the ... , (excluding Japan ), is second with ... continues to face increased healthcare expenditure. In 2013-2014, total government ... from 43.5% in 2008-2009 to 41.2% in 2013-2014. In real ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma ... planned investment of at least $15.8  Million to ... Wilmington, NC . The expansion will ... to meet the growing demands of the pharmaceutical ... site expansion will provide up to 40,000 ...
Breaking Medicine Technology: